We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

MetaVia Inc (MTVA) USD0.001

Sell:$1.55 Buy:$1.81 Change: $0.19 (11.73%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$1.55
Buy:$1.81
Change: $0.19 (11.73%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
Sell:$1.55
Buy:$1.81
Change: $0.19 (11.73%)
Market closed |  Prices as at close on 26 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

MetaVia Inc., formerly NeuroBo Pharmaceuticals, Inc., is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus resulting in body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, GLP-1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.

Contact details

Address:
545 Concord Avenue, Suite 210
CAMBRIDGE
02138
United States
Telephone:
+1 (857) 7029600
Website:
https://www.neurobopharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MTVA
ISIN:
US64132R4048
Market cap:
$13.96 million
Shares in issue:
8.62 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Hyung Kim
    President, Chief Executive Officer, Director
  • Marshall Woodworth
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.